ABSTRACT Dose-response relationships for salbutamol were studied in eight patients suffering from chronic airflow obstruction with no asthmatic features. Each inhaled, double blind, in randomised order 0, 200, 400, 800, and 1600 ug salbutamol on five successive mornings. Before and at intervals up to six hours after the inhalation FEV1, vital capacity, maximum inspiratory and expiratory flow-volume curves, and 12-minute walking distances were measured. Analysis of variance of the results indicated significant dose-response relationships and showed the larger doses to have a longer duration of action. Simple spirometric tests were as useful in providing objective evidence of benefit as maximum inspiratory flows or the 12-minute walking distance. 
Salbutamol is frequently prescribed as an inhaled preparation for patients with chronic airflow obstruction in a dose of 200 or 400 ,tg four times a day. The successful use of much larger doses of nebulised respirator solution in patients with asthma' 2 has led to similar treatment in patients with chronic airflow obstruction. Many appear to show a greater improvement on these higher doses (5 or 10 mg) but it is not clear whether this is related to the dose or to the means of administration. There is some evidence that tests of forced expiration alone, such as FEV,, may not be the most useful for monitoring improvement in such patients because of the effects of dynamic airway compression.3 The relaxed vital capacity (VC),4 12-minute walking distance (12-MD),5 and maximal inspiratory flow at 50% of VC6 have all been suggested as alternatives. We have carried out a dose-response study of inhaled salbutamol powder in patients with chronic airflow obstruction and used these indices in addition to spirometric measurements.
Methods
Eight patients with stable chronic airflow obstruction were studied. Their ages and the results of spirometry and of measurements of lung volumes, transfer factor, and transfer coefficient (Kco) are shown in the table. All had been cigarette smokers and were considerably disabled by breathlessness. Care was taken to exclude patients with asthmatic features from the study by the following criteria for entry: (1) improvement of FEV, not greater than 15% 15 minutes after two puffs of salbutamol; (2) no response to a steroid trial, defined as failure of the FEV, to rise by 15% after 30 mg prednisolone for two weeks; (3) no blood eosinophilia; (4) no sputum eosinophilia; (5) negative responses to skin tests for common allergens.
No patient was studied within one month of a respiratory tract infection. All Repeat flow-volume curves were obtained on each occasion until three reproducible curves were produced. The curves were displayed on a storage oscilloscope and photographed to allow measurement of peak inspiratory flow (PIF). The 12-minute walking distance (12-MD) was measured one hour before and one and four hours after the drug was inhaled.
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For each index of response Newman Keul's method of analysis of variance" was used to compare the overall effects of the different doses on the absolute values recorded over the whole period of measurement. In addition, dose-response curves were constructed for each index at the time of inhalation and one, two, and four hours afterwards, and the significance of the differences between the effects of the different doses was assessed by paired t tests. figure 6 and these give information similar to the spirometric measurements. 
Discussion
A clear relationship between degree of bronchodilatation and dose of inhaled salbutamol has been shown previously in asthmatic patients.9 '°The present study has shown that a gradation of response is also seen in patients with chronic, largely irreversible, airflow obstruction. The longer the period after inhalation the clearer the dose effect became and the larger the dose the longer its duration of action. Prolongation of the effect of salbutamol with larger doses has previously been shown with a nebulised solution delivered by intermittent positive-pressure breathing to asthmatic patients.'0 A large placebo response was observed in the present study and the explanation for this is not clear. All patients had previously used n-stimulants with clinical benefit and their expectations were probably high after a period of abstinence from regular use. The drugs were given in the morning and some improvement could be expected spontaneously at that time of day but the decline after two hours would not be expected if this were the complete explanation.
Although one criterion for entry into the study was failure of the FEVI to improve by 15% 15 minutes after two puffs (200 ,g) of salbutamol from a conventional aerosol, the mean improvement in FEV1 observed during the study 15 minutes after 200 ,ug salbutamol was 20% and after two hours 25%. This paradox may be explained by the different mode of administration or possibly by tolerance to salbutamol at the initial testing, reversed by abstinence from the drug for 10 days before the study. The maximum bronchodilator effect was seen between one and two hours after inhalation for all doses, and it follows that when patients with chronic airflow obstruction are tested for maximal response to a long-acting inhaled , 8- 
